ReviewThe journal of headache and pain2024
Influence of metabolic state and body composition on the action of pharmacological treatment of migraine.
Review in The journal of headache and pain, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Effectiveness of low dose thyroxine in patients with subclinical hypothyroidism and migraine; systematic review and meta-analysis.BMC neurology · 2025Pooled it
- Effectiveness and safety of anti-CGRP monoclonal antibodies for migraine in patients over 65 years: a systematic review.Pain management · 2025Pooled it
- Epidemiological linkage between migraine and diabetes mellitus: a systematic review and meta-analysis.The journal of headache and pain · 2024Pooled it
- Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review.The journal of headache and pain · 2024Pooled it
- Serum serotonin and its association with glycaemic indices and haemoglobin in adults with migraine: a comparative cross-sectional study.BMC neurology · 2026Observational
- Sex-specific considerations in migraine therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Oxidative stress and antioxidant therapeutics in autism spectrum disorder: a biochemical and structure-activity relationship perspective.Molecular diversity · 2026Review
- Simultaneous Use of Continuous Glucose Monitoring (CGM) Systems and the Remote Electrical Neuromodulation (REN) Wearable for Patients with Comorbid Diabetes and Migraine: An Interventional Single-Arm Compatibility Study.Journal of clinical medicine · 2026Article
- Migraine in men - differences in phenotype and treatment patterns: results from the Migraine in Poland cross-sectional national survey.The journal of headache and pain · 2025Article
- A Comprehensive Review of the Role of the Microbiota-Gut-Brain Axis via Neuroinflammation: Advances and Therapeutic Implications for Ischemic Stroke.Biomolecules · 2025Review
- Metabolic Dysfunction and Dietary Interventions in Migraine Management: The Role of Insulin Resistance and Neuroinflammation-A Narrative and Scoping Review.Brain sciences · 2025Review
- Absorption of Toxicants from the Ocular Surface: Potential Applications in Toxicology.Biomedicines · 2025Review
- Migraine in men.The journal of headache and pain · 2025Review
- Combining treatments for migraine prophylaxis: the state-of-the-art.The journal of headache and pain · 2024Review
- Association between severe headache or migraine and lipid accumulation product and visceral adiposity index in adults: a cross-sectional study from NHANES.Lipids in health and disease · 2024Article
- Comparison of gepant effects at therapeutic plasma concentrations: connecting pharmacodynamics and pharmacokinetics.The journal of headache and pain · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a disabling neurovascular disorder among people of all ages, with the highest prevalence in the fertile years, and in women. Migraine impacts the quality of life of affected individuals tremendously and, in addition, it is associated with highly prevalent metabolic diseases, such as obesity, diabetes mellitus and thyroid dysfunction. Also, the clinical response to drugs might be affected in patients with metabolic disease due to body composition and metabolic change. Therefore, the efficacy of antimigraine drugs could be altered in patients with both migraine and metabolic disease. However, knowledge of the pharmacology and the related clinical effects of antimigraine drugs in patients with metabolic disease are limited. Therefore, and given the clinical relevance, this article provides a comprehensive overview of the current research and hypotheses related to the influence of metabolic state and body composition on the action of antimigraine drugs. In addition, the influence of antimigraine drugs on metabolic functioning and, vice versa, the influence of metabolic diseases and its hormonal modulating medication on migraine activity is outlined. Future exploration on personalizing migraine treatment to individual characteristics is necessary to enhance therapeutic strategies, especially given its increasing significance in recent decades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.